Sitemap
Pages
- NAMs Platform
- Newsletter
- Non-Tumor Disease Mouse Model
- Large Animal DMPK Services
- IND-Enabling Studies
- Pharmacology Services
- Biology
- Boston Innovation Center
- Analytical Chemistry Services
- Carbohydrate Synthesis
- Flow Chemistry Platform
- Careers
- Catalyst Screening
- Peptide Platform
- Chemistry
- PROTAC
- ADC Platform
- SiRNA Platform
- AOC Biology
- Digestive System Disease Models
- Ocular Disease Models
- Cardiovascular & Metabolic Disease Models
- CNS Pharmacology Models
- Inflammation & Immune Disease Models
- Humanized Mouse Tumor Models
- Syngeneic Mouse Models
- Orthotopic Mouse Models
- PDX Models
- CDX Models
- Contact
- Sitemap
- In Vivo models
- Preclinical Research
- Resources
- Advanced technology platforms
- Safety Assessment Services
- Drug Discovery
- CMC Development
- DMPK
- About
- Homepage
- Privacy Policy
Categories
Post Content
- Symposium on Biomedical Innovation between Zhangjiang Pharma Valley and Boston
- KSNS 2026
- EFMC-ACSMEDI 2026
- BIO 2026
- Leveraging a Humanized SLE Mouse Model to Evaluate Next-Generation Immune-Cell-Targeted Therapeutics (Download)
- Integrated Mass Spectrometric Workflows Enabling Next-Generation Conjugate Therapeutics in Cancer Research (Download)
- From Sequence Design to AOC Production Medicilon’ s End-to-End RNAi Development Platform (Download)
- ASMS 2026
- Developing PDX-Derived Organoid Models for Efficacy Evaluation of Anticancer Therapies (Download)
- BIO 2026
- Nordic PMF 2026
- AACR 2026 Special Report: An In-Depth Review of Medicilon’s Three Technical Posters | Bilingual
- ICDD 2026
- Medicilon Signs Five-Year Strategic Cooperation Agreement with BioPartners X to Jointly Promote Innovative Drug R&D
- Medicilon and Protheragen Forge Strategic Partnership to Build a Collaborative “Project + Platform” Model
- AOC Development: Conjugation Site Selection, DAR Control & In Vitro Testing | Full Webinar
- BioTrinity 2026
- Medicilon and Hailu Biotech of Yangtze River Pharmaceutical Group Forge Strategic Cooperation to Accelerate New Drug R&D and Global Outreach
- Oligonucleotide Therapeutics: Conjugation Chemistry & In Vitro Activity Assessment
- BIO-Europe Spring 2026
- 【Case Study】New Approach Methods NAMs
- Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche
- AACR 2026
- 【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)
- 【Case Study】IND Completion in 12 Months (Small-Molecule NCE)
- DDC 2026
- SOT 2026
- Building a New-Drug Expressway Together, Medicilon 2025 Year-End Review
- Medicilon Congratulates AI-Driven Biotech Insilico Medicine on Its HKEX Debut in Hong Kong’s Largest Biotech IPO of 2025
- Boston Non-Tumor Models Innovation
- Efficient Collaboration Earns High Praise: RayThera Honors Medicilon with “Excellent Partnership Award”
- Medicilon | Featured Sponsor for ACCESS ASIA BD Forum @ JPM 2026
- Advancing a New Paradigm in Drug Development: Medicilon and Xellar Biosystems Forge a Strategic Partnership
- Medicilon Earns OECD GLP Certification from Hungary, Strengthening Global Compliance Network
- Medicilon Empowers Strategic Partner SAPU to Obtain Clinical Trial Approval for Sapu003 in Australia
- Medicilon Receives International Accreditation Again! Successfully Obtains OECD GLP Certificate
- 【White Paper】Navigating the DMPK Gauntlet: A Strategic Analysis of the Interconnected Challenges Shaping the Future of Drug Development
- Medicilon: Innovating Globally at CMC-China Expo 2025
- Novamab Announces NMPA CDE Approval of IND for LQ036, the World’s First Inhaled Nanobody for Moderate-to-Severe Asthma
- 【White Paper】Patient-Derived Xenograft Organoids: Advancements and Applications in Precision Oncology
- China &US Dual Filing Secured! Medicilon Supports Sungening’s SG-1001 in Achieving FDA IND Clearance
- Peptide Therapeutics: Preclinical Strategy
- 【Blog】PDX-Derived Organoids: How This Mini-Tumor Transforming Cancer Research?
- Medicilon Highlights at the 2025 CBA-China Conference
- Medicilon Supports BIOTIME in Securing Dual China-US Approvals for CDC7 Inhibitor BIOT-006
- BIK Therapeutics and Medicilon Sign Strategic Collaboration Agreement to Accelerate Oncology Drug Innovation.
- Boston Innovation Meets ADME Precision
- Medicilon Passes FDA Inspection, Reinforcing Global R&D Excellence
- Empowering Innovation in Regenerative Medicine: Medicilon’s ELU42 IND Team Wins Eluciderm’s “Excellent Service Award”
- Medicilon Celebrates Nanolattix Group’s T320 ADC Drug Approval in China, the US, and Australia
- Medicilon—Developing PDX-Derived Organoid Models for Efficacy Evaluation of Anticancer Therapies (Download)
- Medicilon Appoints Dr. Jian Ge as EVP of Preclinical Research Division
- Medicilon Supports Moon Biotech’s Groundbreaking MNO-863 Probiotic Drug – Achieves Nearly 10% Weight Loss in 4 Weeks and Secures Dual Clinical Trial Trial Approvals
- Zero Defects! Medicilon Supports MeiJi BioPharma’s Oral Paclitaxel Soft Capsule in Gaining FDA IND Approval
- Global First! Medicilon Powers Tyercan’s Breakthrough Anti-Tumor Protein-Drug Tye1001 to U.S. and China IND Clearance
- Medicilon DMPK & Bioanalysis Services (Download)
- Medicilon—High Quality Integrated Drug R&D Services (Download)
- Medicilon Large Animal Pharmacodynamic Research Service Platform (Download)
- Medicilon Supports Partner Nuoyuan Medical Equipment Co., Ltd. in Securing FDA IND Approval for Class 1 Innovation Drug Pemefolacianine
- A Decade of Collaboration: Medicilon Supports SinoRDA in Achieving Approval for Linaprazan Glurate
- Medicilon Supports Strategic Partner CGeneTech in Achieving Approval for Next-Generation DPP-4 Inhibitor
- Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
- Medicilon Supports Partner Jemincare in Securing Clinical Approval for JM045 Sustained-Release Microspheres
- Large Animal Models: Essential Tools in Disease Research
- PDXO Model: A Significant Advancement in Precision Oncology
- Medicilon Boston’s Second R&D Center Grandly Sets Sail
- Did You Know That Medicilon Can Handle DMPK Studies?
- Medicilon Supports Jemincare’s JMX-2002 Liposome Injection Clinical Trial Approval
- Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
- Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout
- Medicilon 20th Anniversary – Keep pace with the times in innovation, thanks for having you
- Medicilon’s GLP-1 New Drug R&D Service
- Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates
- The Role of the Ames Test in Predicting the Genotoxicity of Impurity Compounds in Drugs
- Aim at chemical synthesis through Ibuprofen
